CSL Shares Gain Some Ground Into The Weekend: The Latest Look

CSL shares (ASX:CSL) have finally found some support, staging something of a recovery ahead of the weekend, as the second best performing name on the ASX 200 for the day. The CSL share price climbed 5.75% on the day to close at A$97.91, having just come off their lowest levels in 10 years, as director purchases and healthcare sector strength provided some welcome relief.

The rebound lifted CSL shares into positive territory on the week, up 1.35%, marking a tentative stabilisation after the stock plunged to A$90 in the wake of management’s sobering outlook reset. The A$90 level, representing a decade low, appears to have attracted value-oriented buyers willing to step in after the sharp de-rating. Friday’s gain coincided with broader strength across the healthcare sector on the ASX, suggesting some of the move reflected sector rotation rather than CSL-specific catalysts. Still, the bounce from technical lows signals markets may be moving past initial panic, even as fundamental concerns linger.

Despite the weekly gain, CSL remains deeply underwater over the past year, with a 43% drop YTD, and 59.7% decline over the past 12 months. With shares having looked deeply oversold, with an RSI in the low 20’s ahead of today’s move, the bounce moves shares into the mid 30’s ahead of the weekend.

Insider Confidence

Adding to Friday’s positive tone, CSL disclosed that director Carolyn Hewson AO purchased almost A$100,000 worth of shares on-market this week. The transaction follows similar purchases by interim chief executive Gordon Naylor and fellow director Watkins, who collectively acquired several hundred thousand dollars worth of stock around the A$98 mark in recent sessions.

Insider buying at depressed price levels is typically interpreted by markets as a vote of confidence that the sell-off has been overdone. The timing, coming immediately after a major guidance cut and impairment announcement, suggests board members and senior management view the risk-reward equation as skewed to the upside at current valuations. While the absolute dollar amounts are modest relative to CSL’s market capitalisation, the symbolic value of executives deploying personal capital at these levels provides a counterweight to the credibility damage inflicted by repeated guidance misses.

Why are CSL shares down so much anyway?

CSL’s recent troubles stem from a confluence of headwinds across its key business units. The company flagged approximately US$650 million in combined revenue pressures for FY26, driven by three main factors: US immunoglobulin channel inventory normalisation (around US$300 million impact), China albumin market value decline despite stable volumes (roughly US$200 million), and a combined US$150 million hit from paused Iran sales linked to Middle East conflict and increased competition in iron therapy through CSL Vifor.

The guidance downgrade was accompanied by approximately US$5 billion in non-cash, pre-tax impairments across FY26 and FY27, largely tied to CSL Vifor and related assets. The write-downs reflect the company’s acknowledgment that returns on its 2022 Vifor acquisition have disappointed, with iron therapy products facing stiffer competition than anticipated and integration proving more challenging than initially modelled.

On the US immunoglobulin front, CSL explained that distributors and hospitals built excess inventory during the post-COVID recovery period and are now working through those stockpiles. While underlying demand for Ig products continues to grow at mid-to-high single-digit rates, reported sales growth will be suppressed as the channel normalises. Management expects this inventory correction to persist through much of FY26 before growth rates return to more normal levels.

In China, CSL has actually gained albumin market share and maintained stable volumes, but pricing pressure has intensified as local competition increases and government procurement policies favour lower-cost options. The combination of volume growth and price decline has resulted in a net revenue headwind, compressing margins in what had been a key growth market.

Structural Questions

Beyond the cyclical inventory and pricing issues, markets are beginning to grapple with potential structural challenges to CSL’s business model. Novel therapies for autoimmune diseases, including FcRn antagonists and complement inhibitors, could eventually erode demand for traditional immunoglobulin products if they prove superior in clinical practice. While these competitive threats remain years away from meaningfully impacting CSL’s volumes, their mere existence has introduced a new layer of long-term risk that wasn’t priced in during the company’s premium-multiple era.

The Vifor acquisition, completed for approximately US$12 billion in 2022, has emerged as a strategic misstep. CSL paid a full price for assets that have since faced intensifying competition in iron therapy, particularly from newer oral formulations and biosimilars. The impairments announced in recent weeks represent management’s acknowledgment that expected returns will fall short of acquisition underwriting assumptions. This credibility hit compounds earlier disappointments around plasma collection costs and Ig pricing dynamics.

Leadership uncertainty adds another layer of complexity. The company is currently led by an interim CEO following the departure of its previous chief executive, and markets remain in the dark about succession plans and strategic direction under new permanent leadership. Board composition and governance practices have also drawn scrutiny, particularly given the scale of value destruction over the past 18 months.

Analysts Split From Here

The guidance reset has forced Wall Street and Australian brokers to recalibrate their models and price targets, with outcomes ranging from cautiously optimistic to decidedly bearish. Morgans reduced its forecasts and target price to A$147.59 following the downgrade, citing the China albumin, US Ig, Iran, and Vifor issues. Importantly, however, the broker maintained its buy recommendation, framing current headwinds as cyclical rather than structural. At A$147.59, Morgans’ target implies roughly 50% upside from Friday’s close, suggesting the firm views CSL’s franchise quality as intact despite near-term turbulence.

Macquarie took a more conservative stance, slashing its target to A$111 and expressing concern not just about earnings visibility but also about ongoing management uncertainty. The broker’s price objective sits only modestly above current trading levels, reflecting scepticism that CSL can quickly rebuild credibility after multiple guidance disappointments. Macquarie explicitly flagged the interim CEO situation and questions around strategic execution as factors weighing on the appropriate valuation multiple.

Jefferies recently downgraded CSL from buy to hold, cutting its target to A$108 from A$195. The firm noted that FY27 net profit forecasts now sit roughly 10% below prior consensus, reflecting compounded pressures across CSL Behring and Vifor that will take time to resolve. Ord Minnett similarly maintains a hold rating, highlighting continued uncertainty around key markets and the FY27 outlook.

The broker community has shifted from near-universal buy ratings on CSL as recently as 18 months ago to a more divided stance, with hold ratings now common and price targets spanning a wide range. This dispersion reflects genuine uncertainty about the company’s medium-term earnings trajectory and the appropriate multiple for a franchise that has lost some of its predictability premium.

Path Forward Uncertain

Despite the litany of challenges, several factors support the argument that CSL shares have reached a cyclical low rather than embarking on a structural decline. At current levels, the stock trades at roughly 9 to 10 times enterprise value to EBITDA, well below its historical average and below many global biopharmaceutical peers. For a business with strong market positions in plasma therapies and a track record of innovation, that valuation implies a degree of pessimism that may prove excessive if execution stabilises.

The coming quarters will prove critical in determining whether CSL’s rebound from A$90 marks the beginning of a sustained recovery or merely a technical bounce within a longer downtrend. Management faces the challenge of delivering clean results without further guidance cuts, rebuilding credibility with markets that have grown sceptical, and demonstrating that the strategic rationale for the Vifor acquisition can still be realised despite current headwinds.

From a technical perspective, the A$90 level now represents important support, with Friday’s bounce suggesting at least some buyers view that zone as attractive. A 10% correction from a major move could still be a typical test for markets, whilst the technicals ‘cool off’, and the longer term trend can continue. We would be watching for a move above $100, and some real strength in volume as signs that the worst may be behind CSL. Whilst the long term investment case may be becoming more compelling at these levels, there remains a fear of the dead cat bounce that we would want to see put to bed.